

## ***Circulation* 2006 – Vascular Biomarkers and Surrogates in Cardiovascular Disease**

In June 2006 the American Heart Association Journal, *Circulation*, published a Special Report Article authored by Jean-Claude Tardif, MD; Therese Heinonen, DVM; David Orloff, MD; and Peter Libby, MD entitled **Vascular Biomarkers and Surrogates in Cardiovascular Disease**. The article summarized the authors' perspective distilled from the proceedings of the 2003, 2004 and 2005 Cardiovascular Biomarker and Surrogate Endpoints Symposia (***Attachment***).

## **2006 Cardiovascular Biomarkers and Surrogate Endpoints Symposium**

Most recently, the Forth Annual Cardiovascular Biomarkers and Surrogate Endpoints Symposium was held in September 2006 and co-sponsored by the Montreal Heart Institute and the US FDA Center for Food Safety and Applied Nutrition, further expanding the global reach of this initiative. The 2006 program included focused presentations and discussions on cerebrovascular disease, thrombosis, functional imaging, NIH initiatives, pre-clinical issues, nutrition, and special considerations of gender, race and ethnicity (***Appendix G***). Significant new contributions were made by representatives from the US FDA pharmacology division, and the United States Department of Health and Human Services Agency for Healthcare Research and Quality (AHRQ). Additionally, important contributions were made by Health Canada with continued contributions on the European perspective from EMEA. The keynote address was given by Dr. Scott Gottlieb, Deputy Commission of the United States Food and Drug Administration followed by presentations and discussions led by over 35 invited faculty members (***Appendix H***). In 2006, the symposium attracted approximately 250 attendees from over 60 institutions (***Appendix I***).